Accordingly, the combination of B-Raf and MEK inhibitors has been emerged as a strategy to delay or prevent the development of resistance and increase of secondary cancers, by preventing this paradoxical activation of MEK/ERK signaling1, 7, 8. Here, MAP2K7 is linked to cancer.